Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial and graft occlusions: a randomized trial

Radiology
M F MeyerovitzD P Harrington

Abstract

A randomized prospective trial was undertaken to compare intraarterial administration of recombinant human tissue-type plasminogen activator (rt-PA) with urokinase (UK) in 32 patients with peripheral arterial or bypass graft occlusions. Sixteen patients were randomized to receive rt-PA and 16 to receive UK. The rt-PA dose was administered as a 10-mg bolus into the thrombus, followed by 5 mg/h for up to 24 hours. The UK dose was administered as a 60,000 IU bolus into the thrombus, followed by 240,000 IU/h for 2 hours, 120,000 IU/h for 2 hours, and 60,000 IU/h for up to 20 hours. Serial arteriograms were obtained at baseline and at 4, 8 or 16, and 24 hours. The endpoint was defined as 95% of greater clot lysis. The cumulative numbers of patients with successful thrombolysis (rt-PA vs UK) were four vs none at 4 hours, seven vs one at 8 hours, seven vs three at 16 hours, and eight vs six at 24 hours. Lysis occurred more rapidly in the rt-PA group (P = .04). Major bleeding complications occurred in five rt-PA patients and two UK patients (P = .39). At 24 hours, fibrinogen levels were significantly lower in the rt-PA group than in the UK group (P = .01). There was no apparent difference in 30-day clinical success.

Citations

Sep 1, 2006·Seminars in Interventional Radiology·Harry L Morrison
Jan 1, 1994·Postgraduate Medical Journal·D A Shields, J H Scurr
Oct 3, 1998·Intensive Care Medicine·N CurzenA Timmis
Nov 1, 1990·The Japanese Journal of Surgery·A Whittemore
Oct 3, 2002·Thrombosis Research·Vincenzo Costantini, Massimo Lenti
Jul 25, 2003·Journal of Endovascular Therapy : an Official Journal of the International Society of Endovascular Specialists·Thomas ZellerFranz-Josef Neumann
Sep 5, 1998·The Surgical Clinics of North America·M D MaloneA J Comerota
Nov 11, 1991·Cardiovascular and Interventional Radiology·S L KaufmanW J Casarella
Feb 18, 2010·Cardiovascular and Interventional Radiology·Dimitrios Tsetis
Apr 15, 2008·Expert Opinion on Biological Therapy·Mireille A Moise, Vikram S Kashyap
Oct 1, 1995·Chest·G P Clagett, W C Krupski
Oct 1, 1992·Chest·G P ClagettE W Salzman
Jan 1, 2013·Journal of Vascular and Interventional Radiology : JVIR·Nilesh H PatelUNKNOWN CIRSE and SIR Standards of Practice Committees
Nov 20, 1998·Chest·M R Jackson, G P Clagett
Feb 7, 2001·Chest·M R Jackson, G P Clagett
Dec 5, 2003·Journal of Vascular and Interventional Radiology : JVIR·Mahmood K RazaviLawrence V Hofmann
Sep 30, 2003·Journal of Vascular and Interventional Radiology : JVIR·Nilesh PatelUNKNOWN Society of Interventional Radiology Technology Assessment Committee
Jun 5, 2004·Journal of Vascular and Interventional Radiology : JVIR·Kenneth Ouriel
Jun 5, 2004·Journal of Vascular and Interventional Radiology : JVIR·Jeffrey Eaton HullJames A Urso
Jan 8, 2004·Journal of Vascular and Interventional Radiology : JVIR·Mahmood K RazaviLawrence V Hofmann
Apr 6, 2004·Journal of Vascular and Interventional Radiology : JVIR·Michael R Grunwald, Lawrence V Hofmann
Sep 17, 2011·Annals of Vascular Surgery·Brian G HynesMichael R Jaff
Jun 24, 2010·Journal of Vascular and Interventional Radiology : JVIR·Arun J SebastianDuncan F Ettles
Aug 1, 1991·Journal of Vascular and Interventional Radiology : JVIR·D C SmithJ C Westengard
Jul 1, 1995·Journal of Vascular and Interventional Radiology : JVIR·C J BeroG G Nicholas
Nov 1, 1995·Journal of Vascular and Interventional Radiology : JVIR·K Ouriel
Jul 1, 1996·Journal of Vascular and Interventional Radiology : JVIR·M DubéJ R Cusson
Oct 21, 2000·Journal of Vascular and Interventional Radiology : JVIR·S J SavaderA C Oteham
Jan 15, 2002·Journal of Vascular and Interventional Radiology : JVIR·Aravind ArepallyBruce Perler
Aug 6, 2000·Journal of Vascular and Interventional Radiology : JVIR·K OurielD Gibbens
Apr 29, 2000·Journal of Vascular and Interventional Radiology : JVIR·K Valji
Sep 30, 2003·Journal of Vascular and Interventional Radiology : JVIR·UNKNOWN Working Party on Thrombolysis in the Management of Limb Ischemia
May 1, 2007·The Veterinary Clinics of North America. Small Animal Practice·Kari V Lunsford, Andrew J Mackin
May 8, 2001·Journal of Vascular and Interventional Radiology : JVIR·N PatelUNKNOWN Technology Assessment Committee of the Society of Cardiovascular & Interventioanal Radiology
Nov 24, 2004·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·David E AllieCraig M Walker
Jun 16, 2015·Seminars in Vascular Surgery·Reagan L Ross, Adam W Beck
Sep 11, 2007·Orvosi hetilap·János MikitaJudit Tóth

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The Cochrane Database of Systematic Reviews
Iain RobertsonD C Berridge
The Cochrane Database of Systematic Reviews
Antonio J RuffoloAgustín Ciapponi
© 2021 Meta ULC. All rights reserved